GRCE
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (GRCE) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 47.8, with 1/3 trend checks passing.
GRCE with MA50 and MA200
Key levels & signals
GRCE valuation multiples (TTM)
GRCE analyst consensus
Grace Therapeutics, Inc. (GRCE) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $2.38, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 1.5% and below the 200-day moving average by 26.6%.
GRCE currently has an RSI reading of 47.8, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
This page is designed to help you quickly understand what the GRCE chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about GRCE
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.